Regenxbio Inc. (RB0)
XSTU 
Summary
RB0 Chart
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity
Regenxbio is rated a 'risky buy' due to high volatility, regulatory setbacks, and significant near-term catalysts. RGNX faces a clinical hold on RGX-121 for Hunter Syndrome, complicating milestone payments and royalty streams, but maintains sufficient cash runway into Q4 2027. Pivotal data for the AbbVie-partnered eye disease program and BLA submission for RGX-202 in DMD represent major binary catalysts by year-end and 2027.
Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial
Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company's investigational therapy for Hunter syndome.
Regenxbio Inc. (RB0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Regenxbio Inc. ever had a stock split?
Regenxbio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Curran Simpson CEO | XSTU Exchange | 75901B107 CUSIP |
| US Country | 371 Employees | - Last Dividend | - Last Split | 17 Sep 2015 IPO Date |
Overview
REGENXBIO Inc. is a front-runner in the clinical-stage biotechnology industry, specializing in the provision of pioneering gene therapies. Based in Rockville, Maryland, the company was established in 2008 and has been dedicated to addressing genetic defects through the delivery of functional genes into cells. This innovative approach is facilitated by their proprietary NAV Technology Platform, an adeno-associated virus gene delivery mechanism. This platform stands at the core of REGENXBIO’s operations, underpinning the development of its diverse range of gene therapy product candidates. These candidates target a variety of chronic and severe genetic diseases, asserting REGENXBIO’s pivotal role in the evolution of gene therapy in the United States. Furthermore, the company not only focuses on developing its own product lineup but also licenses this groundbreaking NAV Technology Platform to other entities within the biotechnology and pharmaceutical industries, enhancing the widespread applicability of its research and developments. The collaboration with AbbVie Global Enterprises Ltd. for the development of ABBV-RGX-314 outside the United States exemplifies REGENXBIO’s commitment to global health improvements through strategic partnerships.
Products and Services
ABBV-RGX-314: This innovative product candidate is a gene therapy aimed at treating wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases. ABBV-RGX-314’s development is in collaboration with AbbVie Global Enterprises Ltd., showcasing REGENXBIO’s strength in forming strategic partnerships to enhance its product offerings.
RGX-202: Currently in Phase I/II clinical trial, RGX-202 is designed to address Duchenne muscular dystrophy. This product highlights the company’s commitment to tackling severe genetic disorders and improving muscle function and quality of life for affected individuals.
RGX-121: Targeting mucopolysaccharidosis type II, RGX-121 is a gene therapy that is advancing through Phase III clinical trials. This product represents REGENXBIO’s efforts to address rare and serious genetic conditions with innovative gene transfer technologies.
RGX-111: Developed for the treatment of mucopolysaccharidosis type I, RGX-111 is another exemplar of the company’s dedication to combating rare genetic diseases through cutting-edge gene therapy solutions.
RGX-181: Focused on late infantile neuronal ceroid lipofuscinosis type II, RGX-181 is part of REGENXBIO’s pipeline aimed at treating rare neurological genetic conditions, demonstrating the company’s pursuit of solutions for complex genetic disorders.
RGX-381: Specifically developed to address the ocular manifestations of CLN2 disease, RGX-381 exemplifies REGENXBIO’s commitment to expanding its therapeutic reach into various aspects of genetic conditions, underlining the versatility and breadth of its product pipeline.
These products underline REGENXBIO Inc.'s forte in leveraging its NAV Technology Platform to address a spectrum of genetic disorders. By focusing on such diverse therapeutic areas, the company not only highlights its scientific and technical expertise but also underscores its commitment to improving patient outcomes across a range of challenging genetic conditions.
